Peptide LexiconAll compounds

Voclosporin (Lupkynis): The Cyclic Peptide Approved for Lupus Nephritis, and What Its Trial Showed

Voclosporin is a ring of eleven amino acids, a close chemical relative of cyclosporine, approved in the United States in January 2021 as Lupkynis for active lupus nephritis. This entry covers the molecule, how it suppresses the immune system, the 357-patient trial behind the approval and the label's boxed warning.

Approved drug (US, 2021)Prescription onlyBoxed warning

Caroline S · Published 2026-11-16

Length

11 amino acids in a ring — C63H111N11O12, molecular weight 1,214.6 (Lupkynis label)

Sequence

Cyclic undecapeptide; differs from cyclosporine at the first residue, which carries a longer (6E)-nonadienoyl side chain (Lupkynis label, section 11)

Origin

Semi-synthetic analogue of cyclosporine, itself a fungal product

Last reviewed

2026-11-16

What is it good for?

Voclosporin is a prescription immunosuppressant approved in the United States for adults with active lupus nephritis — kidney inflammation caused by lupus — and only in combination with background immunosuppressive treatment. In the 357-patient trial behind the approval, 41% of patients on voclosporin reached a complete kidney response at one year against 23% on placebo, both groups also taking mycophenolate and steroids.

Illustration: A small, corked glass bottle holds a white and deep green cyclic peptide model.
Illustration

What it is

Voclosporin is a ring of eleven amino acids — a cyclic peptide — and a close chemical relative of cyclosporine. It is sold in the United States as Lupkynis, approved on 22 January 2021 for adults with active lupus nephritis, the kidney inflammation that affects many people with systemic lupus (Drugs@FDA, NDA 213716, sponsor Aurinia).

The label's chemical name lists the eleven residues of the ring: one unusual amino acid with a long side chain, then α-aminobutyric acid, N-methylglycine, N-methylleucine, valine, N-methylleucine, alanine, D-alanine and three more N-methylated residues. That is the cyclosporine ring. The difference sits in the first residue, whose side chain is written on the label as a (6E)-nonadienoyl group (Lupkynis label, section 11, revision dated 2026-08-25). The label also notes that the drug substance is 90–95% the trans form of that side chain.

Property Value Source
Length 11 amino acids, cyclic Lupkynis label, section 11
Formula C63H111N11O12 Lupkynis label
Molecular weight 1,214.6 g/mol Lupkynis label
Solubility Practically insoluble in water (under 0.1 g/L at 20 °C) Lupkynis label
Form sold Soft gelatin capsule, 7.9 mg Lupkynis label, section 3

The site's cyclosporine entry covers the parent molecule.

How it works

Voclosporin is a calcineurin inhibitor. Calcineurin is an enzyme inside T cells, a type of white blood cell; when it is switched on, the cell produces signals that drive inflammation. Blocking it damps that response. The label places voclosporin in the same drug class as cyclosporine and tacrolimus. In lupus nephritis the immune system attacks the kidney's filters, so suppressing it aims to stop the damage and reduce the protein leaking into the urine.

What the trials showed

The approval rests on AURORA 1, a 52-week, randomised, double-blind trial at 142 sites in 27 countries, published in the Lancet in 2021 (PMID 33971155). It enrolled 357 adults with biopsy-proven lupus nephritis. Every patient received mycophenolate mofetil and a tapering course of low-dose steroids; half also received voclosporin, half placebo.

Outcome at week 52 Voclosporin Placebo Source
Complete renal response 73 of 179 (41%) 40 of 178 (23%) AURORA 1 abstract
Odds ratio 2.65 (95% CI 1.64–4.27) — AURORA 1 abstract
Serious adverse events 37 of 178 (21%) 38 of 178 (21%) AURORA 1 abstract
Pneumonia (serious) 7 (4%) 8 (4%) AURORA 1 abstract
Deaths 1 5 AURORA 1 abstract

"Complete renal response" had a strict definition on the label: urine protein-to-creatinine ratio of 0.5 mg/mg or less, kidney function held, and no more than a low steroid dose late in the year. A patient who needed rescue medication counted as a non-responder.

The earlier AURA-LV trial (Kidney International 2019, PMID 30420324) compared two voclosporin doses with placebo on the same background treatment; it is the dose-ranging study AURORA 1 followed.

What the record does not establish: AURORA 1 measured one year. Whether the higher response rate prevents kidney failure over a decade is not shown by these trials, and the label states that safety and efficacy have not been established with cyclophosphamide, another common lupus nephritis drug.

Safety on the label

The Lupkynis label carries a boxed warning: an increased risk of malignancies and serious infections, with voclosporin as with other immunosuppressants, that may lead to hospitalisation or death.

The label describes a studied regimen of 23.7 mg twice daily, three of the 7.9 mg capsules per dose. That figure is reported here because it is on the label; dosing is decided by the prescriber.

Where it stands

Voclosporin is a prescription drug with one US indication. It is not a supplement, a research peptide or a wellness product, and nothing on the record supports using it outside lupus nephritis. Decisions about it belong to the nephrologist or rheumatologist treating the kidney disease.

Sources opened 2026-11-16: Lupkynis prescribing information (openFDA, revision 2026-08-25); Drugs@FDA NDA 213716; Rovin et al., Lancet 2021 (PMID 33971155); Rovin et al., Kidney International 2019 (PMID 30420324); PubMed and ClinicalTrials.gov API v2 counts.

What the research shows

More patients reach a complete kidney response in lupus nephritis

AURORA 1, Lancet 2021 (PMID 33971155): 357 patients, complete renal response at week 52 in 73 of 179 (41%) on voclosporin vs 40 of 178 (23%) on placebo, odds ratio 2.65

Earlier dose-ranging trial pointed the same way

AURA-LV, Kidney International 2019 (PMID 30420324): randomised, double-blind, dose-ranging comparison against placebo, both on mycophenolate and steroids

Suppresses T-cell activation by blocking calcineurin

Lupkynis label: described as a calcineurin-inhibitor immunosuppressant

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Lupkynis, NDA 213716, Aurinia; original approval 2021-01-22 (Drugs@FDA). Label revision in openFDA dated 2026-08-25.

Form on the label

Soft gelatin capsules, 7.9 mg voclosporin each. The label's studied regimen was 23.7 mg twice daily — reported here as the label states it, not as guidance.

Published record

PubMed: 236 records naming voclosporin, 16 tagged as randomised trials. ClinicalTrials.gov: 29 studies mention it, 28 list it as an intervention (2026-11-16).

Frequently asked questions

What is voclosporin?

A prescription immunosuppressant sold as Lupkynis. Chemically it is a ring of eleven amino acids, a modified form of cyclosporine, and it works by blocking the enzyme calcineurin in immune cells.

Is voclosporin a peptide?

Yes. It is a cyclic undecapeptide — eleven amino acids joined head to tail in a ring — several of them N-methylated, as in cyclosporine.

What is Lupkynis approved for?

For adults with active lupus nephritis, in combination with a background immunosuppressive regimen. The US approval date is 22 January 2021.

How is voclosporin different from cyclosporine?

The two share the same ring. Voclosporin's first amino acid carries a longer side chain, according to the chemical name on its label. The two are approved for different uses.

What does the boxed warning on Lupkynis say?

That voclosporin, like other immunosuppressants, increases the risk of malignancies and serious infections that may lead to hospitalisation or death.

Can voclosporin be bought without a prescription?

No. In the United States it is a prescription-only drug approved for one kidney condition, and decisions about it belong to the treating nephrologist or rheumatologist.